Financial Performance - The company's operating revenue for 2021 was ¥529,615,447.55, representing an increase of 8.05% compared to ¥490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥68,507,883.04, a decrease of 25.53% from ¥91,988,592.72 in 2020[18]. - The net cash flow from operating activities was ¥48,149,282.18, down 24.34% from ¥63,639,874.30 in the previous year[18]. - Basic earnings per share for 2021 were ¥1.05, a decline of 31.37% compared to ¥1.53 in 2020[18]. - Total assets at the end of 2021 reached ¥851,423,622.82, an increase of 129.49% from ¥371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders increased by 227.16% to ¥792,918,557.15 from ¥242,361,001.66 in 2020[18]. - The company reported a weighted average return on equity of 17.25%, down from 46.85% in the previous year[18]. - The fourth quarter revenue was ¥133,193,317.74, with a net profit of ¥19,163,573.63 attributable to shareholders[20]. - The company's non-recurring gains totaled CNY 10,287,621.32 in 2021, a decrease of 69.7% from CNY 33,854,842.62 in 2020[24]. - The government subsidies recognized in the current period amounted to CNY 10,971,571.88, down from CNY 34,384,862.30 in 2020[23]. Market and Product Overview - The domestic healthcare expenditure has grown from approximately CNY 2 trillion in 2010 to CNY 7.23 trillion in 2020, with a compound annual growth rate (CAGR) of 13.71%[27]. - The market size for blood plasma substitutes in China was approximately CNY 55.368 billion in 2020, with a CAGR of about 5.99% from 2013 to 2020[28]. - The market for therapeutic crystalloid products in China grew from CNY 0.672 billion in 2013 to CNY 2.363 billion in 2020, achieving a CAGR of 19.68%[29]. - The company's main product, sodium acetate Ringer's injection, holds a market share of nearly 90% in the first half of 2021[32]. - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥465,358,327.89, accounting for 87.87% of total revenue during the reporting period[34][37][43]. - The company achieved sales revenue of ¥64,257,119.66 from Cefotaxime Sodium Injection, representing 12.13% of total revenue[34][37]. Research and Development - The company has obtained 48 patents, including 10 invention patents, 36 utility model patents, and 2 design patents, with 8 invention patents currently under application[34][42]. - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The company emphasizes innovation in R&D, focusing on plasma substitutes and emergency medications, with over 20 products in the research pipeline[43][42]. - The company is advancing multiple R&D projects, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at expanding its product line and market presence[62]. Financial Management and Governance - The company has established a sound financial and accounting management system, with independent accounting professionals managing financial records and making financial decisions[97]. - The company has not faced any disciplinary actions from the China Securities Regulatory Commission or the Shenzhen Stock Exchange regarding internal control issues in 2021[95]. - The company has a complete procurement, production, and sales system, with independent operational sites and decision-making capabilities[96]. - The company has held multiple shareholder meetings in 2021, with attendance rates of 100% and 73.73% for different meetings[99]. - The company has established a remuneration decision-making process based on national laws and regulations, as well as company performance[109]. Employee and Social Responsibility - The company aims to enhance employee training and development, focusing on vocational skills and high-level talent cultivation in 2022[123]. - The company actively engages in corporate social responsibility, including donations to local schools in Changdu, Tibet, to support underprivileged students[146]. - The company has a strong focus on sustainable development, balancing economic and social benefits[146]. Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 20% to 1.8 billion RMB, driven by new product launches and market expansion strategies[153]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market penetration by the end of 2023[155]. - The company aims to invest 200 million RMB in technology upgrades over the next two years to improve production capabilities and reduce costs[152]. Risk Management - The company faces potential risks from the removal of sodium acetate Ringer's injection from local medical insurance directories, which could impact sales growth[30]. - The company is facing risks from the national volume-based procurement policy, with its core product not yet included in the national procurement list, which could adversely affect sales in key regions[87]. - The company has established a comprehensive internal control system to effectively mitigate operational risks[135].

Financial Performance - The company's revenue for Q1 2022 was ¥72,887,112.31, a decrease of 40.23% compared to ¥121,941,030.65 in the same period last year[3] - Net profit attributable to shareholders was ¥8,912,462.89, down 59.10% from ¥21,792,577.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,334,047.77, a significant decline of 92.62% from ¥18,086,835.01 in the previous year[3] - Total operating revenue for the current period was ¥72,887,112.31, a decrease of 40.2% compared to ¥121,941,030.65 in the previous period[16] - Net profit for the current period was ¥8,524,544.62, a decline of 59.3% from ¥20,988,719.93 in the previous period[18] - Operating profit decreased to ¥9,381,414.07, down 60.5% from ¥23,779,164.45[17] - Basic and diluted earnings per share were both ¥0.11, compared to ¥0.36 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥15,632,963.13, compared to a positive ¥21,967,398.51 in the same period last year, marking a 171.16% decrease[3] - Cash flow from operating activities showed a net outflow of ¥15,632,963.13, contrasting with a net inflow of ¥21,967,398.51 in the previous period[21] - Cash and cash equivalents at the end of the period were ¥433,237,666.85, down from ¥119,285,563.08 at the end of the previous period[21] - The company's cash and cash equivalents decreased from ¥610,930,333.64 at the beginning of the year to ¥563,769,166.85 at the end of the reporting period, a decline of approximately 7.7%[12] - Investment activities resulted in a net cash outflow of ¥31,499,953.66, compared to a smaller outflow of ¥1,864,043.94 previously[21] - Financing activities generated a net cash outflow of ¥400,000.00, compared to an outflow of ¥5,309,736.10 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥842,026,922.74, a decrease of 1.10% from ¥851,423,622.82 at the end of the previous year[3] - Total assets decreased from ¥851,423,622.82 to ¥842,026,922.74, a decline of about 1.7%[15] - Total liabilities decreased from ¥62,789,771.85 to ¥45,268,527.15, a reduction of approximately 28.1%[14] - The company's total equity increased from ¥788,633,850.97 to ¥796,758,395.59, an increase of about 1.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,069, with no preferred shareholders[9] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of shares, totaling 46,677,966 shares, with 2,100,000 shares pledged[9] - The number of shares held by the top ten shareholders reflects a concentration of ownership, with the top shareholder alone holding over 58%[9] Operational Challenges - The company's core product, sodium acetate injection, experienced a sales decline due to local medical insurance adjustments, COVID-19 impacts, and a 10% decrease in average selling price[8] - The company reported a significant increase in credit impairment losses of 599.27%, amounting to ¥1,220,031.51, due to a reduction in bad debt provisions[8] - Other income increased by 103.99% to ¥8,327,479.77, primarily due to an increase in government subsidies received[8] Inventory and Receivables - Accounts receivable decreased from ¥98,290,746.40 to ¥69,758,683.26, representing a reduction of about 29%[12] - Inventory increased from ¥9,824,013.58 to ¥12,041,838.71, marking an increase of approximately 22.4%[13] - Accounts receivable financing rose by 81.94% to ¥3,703,173.46, attributed to an increase in received bank acceptance bills[7] Audit and Reporting - The company did not conduct an audit for the first quarter report[22] - The company has not disclosed any new product developments or market expansion strategies in the current report[11]

Financial Performance - The company's operating revenue for 2021 was ¥529,615,447.55, representing an increase of 8.05% compared to ¥490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥68,507,883.04, a decrease of 25.53% from ¥91,988,592.72 in 2020[18]. - The net cash flow from operating activities was ¥48,149,282.18, down 24.34% from ¥63,639,874.30 in the previous year[18]. - Basic earnings per share for 2021 were ¥1.05, a decline of 31.37% compared to ¥1.53 in 2020[18]. - The total assets at the end of 2021 amounted to ¥851,423,622.82, an increase of 129.49% from ¥371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders reached ¥792,918,557.15, up 227.16% from ¥242,361,001.66 in 2020[18]. - The company reported a weighted average return on equity of 17.25% for 2021, down from 46.85% in 2020[18]. - The gross profit margin for the pharmaceutical manufacturing industry was 88.61%, a decrease of 2.34% compared to the previous year[49]. - The total operating cost for the pharmaceutical manufacturing sector was CNY 60,327,111.01, reflecting a year-on-year increase of 35.91%[49]. Revenue Sources - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥465,358,327.89, accounting for 87.87% of total revenue during the reporting period[34][37][43]. - The company achieved sales revenue of ¥64,257,119.66 from Cefotaxime Sodium Injection, representing 12.13% of total revenue[34][37]. - The company’s core product has not yet been included in the national volume-based procurement list, which may affect its sales dynamics in key regions[31]. - The company relies heavily on Sodium Acetate Ringer's Injection for revenue, posing a risk if it cannot maintain its market position or if new product development does not meet expectations[40][42]. Market and Product Development - The company has developed a new production technology for colloidal solutions, which reduces production costs and time while ensuring high product quality[33]. - The company is advancing multiple R&D projects, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at enhancing its product line and market competitiveness[62]. - The company is accelerating the development of new products in the fields of plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to diversify its revenue sources[86]. - The company has established a marketing network covering 29 provinces and municipalities, with its main products sold in over 800 hospitals nationwide, including more than 500 tertiary hospitals[35][41]. Research and Development - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The company has obtained 48 patents, including 10 invention patents, 36 utility model patents, and 2 design patents, with 8 invention patents currently under application[34][42]. - The number of R&D personnel decreased by 4.48% to 64 from 67 in the previous year, with a slight increase in the proportion of bachelor's degree holders[63]. Cash Flow and Investments - Operating cash inflow totaled CNY 611,479,125.47, a 4.25% increase from CNY 586,564,676.94[64]. - Investment cash outflow surged by 323.71% to CNY 215,345,754.75 from CNY 50,823,985.30[64]. - Financing cash inflow increased significantly by 1,257.85% to CNY 557,803,960.00 from CNY 41,080,000.00[64]. - The net increase in cash and cash equivalents was CNY 376,278,639.03, a dramatic rise of 4,126.68% from CNY 8,902,460.58[64]. Corporate Governance - The company maintained independence from its controlling shareholders in business, personnel, assets, institutions, and finance, ensuring a complete and autonomous operational capability[96]. - The company has established a sound financial and accounting management system, with independent accounting professionals managing financial records and making financial decisions[97]. - The company has a total of 7 board members, including 3 independent directors[109]. - The company has a robust internal control system that will continue to be optimized for healthy operations[95]. Employee and Management - The total number of employees at the end of the reporting period was 299, with 107 in the parent company and 192 in major subsidiaries[121]. - The company emphasizes employee training and development, with plans to enhance vocational skills and cultivate high-level talent in 2022[123]. - The total remuneration for the chairman and general manager, Mr. Deng Yong, was CNY 741,500[110]. Dividend Policy - The company plans to conduct at least one profit distribution annually, with cash distribution preferred, contingent on meeting certain financial conditions[126]. - The company proposed a cash dividend of 6.25 CNY per 10 shares, totaling 50,000,000 CNY (including tax) for the reporting period[133]. - The total distributable profit for the year was 115,955,981.72 CNY, with the cash dividend representing 100% of the profit distribution[133]. Social Responsibility and Compliance - The company actively engages in corporate social responsibility, including donations to local schools in Changdu, Tibet, to support underprivileged students[146]. - The company emphasizes compliance with environmental laws and has established internal standards for environmental protection, with no pollution incidents reported[144]. - The company has committed to long-term stability in its shareholding structure, with no plans for share transfers during the lock-up period[149].

Financial Performance - The company's operating revenue for 2021 was CNY 529,615,447.55, representing an increase of 8.05% compared to CNY 490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 68,507,883.04, a decrease of 25.53% from CNY 91,988,592.72 in 2020[18]. - The net cash flow from operating activities was CNY 48,149,282.18, down 24.34% from CNY 63,639,874.30 in the previous year[18]. - The basic earnings per share for 2021 was CNY 1.05, a decline of 31.37% compared to CNY 1.53 in 2020[18]. - The total operating revenue for 2021 was CNY 529,615,447.55, representing an increase of 8.05% compared to CNY 490,164,744.19 in 2020[46]. - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of CNY 465,358,327.89, accounting for 87.87% of total revenue, with a year-on-year growth of 1.46%[46]. - The sales revenue from Cefotaxime Sodium Injection reached CNY 64,244,978.07, making up 12.13% of total revenue, with a significant increase of 103.98% compared to the previous year[48]. - The total operating costs for 2021 were CNY 60,327,111.01, reflecting a year-on-year increase of 35.91%[48]. - The company reported a total R&D investment of ¥24,067,136.11 in 2021, accounting for 4.54% of its operating revenue, a decrease from 4.76% in 2020[60]. Assets and Liabilities - Total assets at the end of 2021 reached CNY 851,423,622.82, an increase of 129.49% from CNY 371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders increased by 227.16% to CNY 792,918,557.15 from CNY 242,361,001.66 in 2020[18]. - The company reported a decrease in accounts receivable by 15.26% to ¥98,290,746.40, indicating improved cash collection efficiency[67]. - The company’s cash and cash equivalents increased to ¥610,930,333.60 by the end of 2021, representing 71.75% of total assets, up from 28.20% at the beginning of the year[67]. Market and Product Development - The company's core product, Sodium Acetate Injection, achieved a domestic market share of nearly 90% in the first half of 2021[32]. - The company has developed a new gel colloid production technology platform, which aims to reduce production costs and improve product quality[33]. - The company is facing risks related to the national and local volume-based procurement policies, which could affect pricing and sales volume of its core products[31]. - The company has several new product developments, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at expanding its product line in the plasma substitutes and psychiatric markets[58]. - The company plans to accelerate the layout of raw material drug production and expand into emergency drugs, pediatric drugs, and psychiatric drugs[84]. - The company is actively developing traditional Chinese medicine products in response to national policies encouraging TCM development[84]. Research and Development - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The number of R&D personnel decreased by 4.48% to 64 in 2021, representing 21.40% of the total workforce[60]. - The company is heavily investing in R&D, aligning its plans with long-term development strategies to enhance innovation capabilities[44]. - The company holds 48 patents, including 10 invention patents, and is in the process of applying for 8 additional invention patents[45]. Governance and Compliance - The company has established a performance evaluation incentive system linking management compensation to business performance, with a transparent hiring process for senior management[93]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors through designated channels[93]. - The company maintains independence from its controlling shareholders in business, personnel, assets, organization, and finance, ensuring autonomous operations[95][96]. - The company has established a robust financial and accounting management system, ensuring independent financial decision-making[96]. - The company has not faced any disciplinary actions from regulatory bodies regarding internal control issues during the reporting period[94]. Cash Dividends and Profit Distribution - The company implemented a stable profit distribution policy, prioritizing cash dividends, with a minimum cash distribution of 10% of the distributable profit for the year[125]. - The cash dividend for the year was set at 6.25 CNY per 10 shares, totaling 50,000,000 CNY, which represents 100% of the total profit distribution[132]. - The company plans to prioritize cash dividends, ensuring that at least 10% of the distributable profits for the year are allocated as cash dividends, provided the company is profitable and has accumulated undistributed profits[158]. - The company will adopt a combination of cash and stock dividends for profit distribution, depending on its cash flow and business growth[158]. Corporate Social Responsibility - The company actively fulfilled its corporate social responsibility by donating school supplies to underprivileged students in April 2021[145]. - The company reported no environmental violations or administrative penalties during the reporting period, adhering strictly to environmental protection laws[142]. - The company has not faced any significant environmental issues and has taken measures to comply with relevant environmental regulations[142]. Future Outlook - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[100]. - New product launches are expected to contribute an additional 300 million CNY in revenue in 2022[100]. - The company has provided a positive outlook for 2022, projecting a revenue growth of 30% based on new product launches and market expansion strategies[164]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for this purpose[153].

Financial Performance - The company's operating revenue for Q3 2021 was ¥152,487,333.59, a decrease of 1.63% compared to the same period last year, while year-to-date revenue increased by 19.73% to ¥396,422,129.81[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,230,327.97, down 15.12% year-on-year, with a year-to-date net profit of ¥49,344,309.41, reflecting an 18.68% decrease[3] - The basic earnings per share for Q3 2021 was ¥0.20, a decline of 16.67% compared to the same period last year, with year-to-date earnings per share at ¥0.82, down 18.81%[3] - The net profit for Q3 2021 was CNY 47,286,377.81, a decrease of 19.5% compared to CNY 58,792,608.79 in Q3 2020[19] - The total profit for the period was CNY 53,319,278.12, down from CNY 66,781,382.09, reflecting a decline of 20.2% year-over-year[19] - Basic and diluted earnings per share were both CNY 0.82, compared to CNY 1.01 in the same quarter last year, indicating a decrease of 18.8%[20] - The total comprehensive income attributable to the parent company was CNY 49,344,309.41, down from CNY 60,680,371.19, reflecting a decline of 18.7%[20] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥881,801,697.35, representing a significant increase of 137.68% compared to the end of the previous year[3] - Total assets as of September 30, 2021, were ¥881,801,697.35, compared to ¥371,006,145.17 at the end of 2020, indicating a growth of 137.5%[17] - The company's total liabilities decreased to ¥111,741,881.49 from ¥130,282,379.57, a reduction of 14.1%[16] - The company's total liabilities stood at CNY 130,282,379.57, with non-current liabilities including lease liabilities of CNY 1,967,645.99[28] - Shareholders' equity totaled CNY 240,723,765.60, with retained earnings of CNY 116,373,429.76[28] - The equity attributable to shareholders increased to ¥773,754,983.52 from ¥242,361,001.66, reflecting a growth of 219.5%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥39,546,864.33, an increase of 12.60%[3] - Cash flow from operating activities generated a net amount of CNY 39,546,864.33, an increase of 12.3% from CNY 35,120,925.99 in the previous year[21] - Cash and cash equivalents increased significantly to ¥637,379,375.20 from ¥104,491,944.61, representing a growth of 510.5%[14] - Cash and cash equivalents at the end of the period totaled CNY 637,379,375.20, significantly up from CNY 80,425,679.46 at the end of the same quarter last year[23] - The company reported cash inflow from financing activities of CNY 537,803,960.00, a substantial increase compared to CNY 41,080,000.00 in the previous year[23] - The cash outflow for investment activities was CNY 3,993,603.56, a decrease from CNY 49,659,358.80 in the same period last year, indicating a reduction in investment spending[23] - The company experienced a net increase in cash and cash equivalents of CNY 532,887,430.59 during the period, compared to a decrease of CNY 15,163,804.57 in the previous year[23] Inventory and Costs - The company experienced a 50.81% decrease in inventory compared to the beginning of the year, mainly due to reduced stock of injectable cefotaxime sodium[8] - Inventory levels decreased to ¥7,294,220.05 from ¥14,827,808.31, a decline of 50.8%, suggesting improved inventory management[15] - Total operating costs amounted to ¥346,559,133.52, up 19.3% from ¥290,473,683.25 year-on-year[17] Research and Development - Research and development expenses for the period were ¥17,360,705.80, slightly up from ¥16,420,025.30, indicating a focus on innovation[17] Accounting and Standards - The company has implemented new leasing standards affecting the financial statements, indicating a shift in accounting practices[24] - The company adopted the new lease accounting standard, resulting in an increase of CNY 1,967,645.99 in both right-of-use assets and lease liabilities[29] - The third quarter report was not audited, indicating preliminary financial data[29] Market Strategy - The company aims to expand its market presence and enhance product offerings, although specific details on new products or technologies were not disclosed in the report[17] - The company has not disclosed any new product developments or market expansion strategies in the current report[28]